罗格列酮对2型糖尿病合并高尿酸血症患者尿酸和颈动脉硬化的影响

目的:观察罗格列酮对2型糖尿病合并高尿酸血症患者尿酸和颈动脉硬化的影响。方法:将2型糖尿病110例合并高尿酸血症患者随机分成两组。对照组维持原治疗;观察组在原治疗基础上给予罗格列酮4 mg/d治疗。治疗前及干预3个月和6个月分别检测血糖、血脂、血尿酸和肾功能,用超声多普勒检查双侧颈动脉内中膜厚度、管腔内径、动脉粥样硬化斑块的数量和类型。结果:给予罗格列酮干预3个月血尿酸水平无明显下降(P>0.05),干预6个月血尿酸水平明显下降(P<0.05)。罗格列酮干预6个月颈动脉内中膜厚度减少、管腔内径增大、动脉粥样硬化斑块的数量减少和类型改变与治疗前相比差异有统计学意义(P<0.05)。结论:罗格列酮能降低合并高尿酸血症的2型糖尿病患者的血尿酸,延缓其颈动脉硬化斑块的发生和稳定斑块,有利于防治糖尿病大血管并发症的发生和发展。

The effect of rosiglitazone on the level of serum uric acid and carotid atherosclerosis in patients with type 2 diabetes mellitus and hyperuricemia

Objective:To observe the effect of rosiglitazone on the level of serum uric acid and carotid atherosclerosis in patients with type 2 diabetes mellitus and hyperuricemia.Methods:One hundred and ten cases of type 2 diabetes mellitus with hyperuricemia were randomly divided into treatment group and control group.The control group received routine therapy alone.The treatment group were treated with rosiglitazone 4 mg/d on the basis routine therapy for six months.The level of serum uric acid,blood glucose,lipid and renal function were detected before and after three and six months.The numbers and types of their carotid atheromatous plaques,carotid inner diameters,carotid intima-media thickness (IMT) were exam- ined by ultrasonography.Results:3-month treatment with rosiglitazone didn't decrease the level of serum uric (P>0.05),but with the treatment prolonged,the level of serum uric was decreased (P<0.05).The decrease of plague number and IMT and the changes of plague all possessed statistical significance after 6-month rosiglitazone treatment (P<0.05).Conclusion: Rosiglitazone can decrease the level of serum uric.And to some extent,it can retard atherosclerosis progression and stabilize arterial plague in patients with type 2 diabetes mellitus and hyperuricemia.